The clinical observation of albumin-bound paclitaxel combined chemotherapy scheme in advanced pan-creatic cancer
YIN Min
ZHONG Yuejiao
co-first author YUAN Yuan
SHEN Bo
Abstract：Objective To investigate the efficacy and adverse reactions of albumin-bound paclitaxel com-bined chemotherapy scheme in advanced pancreatic cancer. Methods 35 patients with advanced pancreatic cancer were treated from August 2010 to July 2014 in the Affiliated Jiangsu Cancer Hospital of NJMU. All of these patients were treated with albumin bound-paclitaxel combined chemotherapy scheme (200~260 mg/m2). After 2 cycles of chemotherapy treatment, the recent curative effects were evaluated according to RECIST crite-ria, the efficacy and adverse reactions were evaluated according to the NCI CTC 3. 0 standard. Results The curative effect of 35 patients can be evaluated reasonably. There are no complete remission ( CR) , 13 cases of partial response ( PR) 16 cases of stable disease ( SD) 6 cases of disease progression ( PD) . There are 7 cases of PR, 5 cases of SD, and 7. 1 months of mPFS in the first line therapy;4 cases of PR, 7 cases of SD, and 4. 8 months of mPFS in the second line therapy;4 cases of SD, 5. 3 months of mPFS in the third line therapy. The main adverse reactions are hair-loss, bone marrow suppression, hepatic injury and diarrhea. Conclusion The curative effect of albumin bound-paclitaxel is definite, it is tolerable for patients and it is worthwhile to promote in the treatment of advanced pancreatic cancer.
Keywords：Albumin-bound paclitaxelAdvanced pancreatic cancerChemotherapyCombined chemotherapyEfficiencyAdverse drug reaction
Publication Date：2016-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 23-25,26 )